On March 24, 2014 Astellas Pharma reported that Astellas has obtained the marketing approval of oral androgen receptor signaling inhibitor, XTANDI capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed an application for approval in Japan in May 2013 (Press release Astellas, MAR 24, 2014, View Source [SID:1234500315]).
Upon receiving this marketing authorization in Japan, Astellas will provide Medivation with a $15 million milestone payment.